RAS mutations are the most common gain-of-function change in human cancer and promise to be a critical therapy target. As a new approach, we have used a surrogate to drug the 'undruggable' (that is, RAS-effector protein-protein interactions inside cancer cells) in preclinical mouse models of RAS-dependent cancers. Using this novel reagent, we have specifically targeted RAS signalling in a transgenic mouse model of lung cancer by directly blockading RAS-effector interactions with an antibody fragment that binds to activated RAS, and show that the interaction of RAS and effectors, such as phosphoinositide 3-kinase and RAF, is necessary for tumour initiation. Further, interference with oncogenic RAS-effector interactions result in control of tumour growth in human cancer cells but, crucially, does not necessarily cause tumour regression. These findings support the concept that ablating RAS-dependent signalling in cancer will have chemo-preventive effects that confer a chronic state in cancer and suggest that mutant RAS-targeted therapies may require conjoint targeting of other molecules and/or current cancer therapeutic strategies (for example, radiotherapy and chemotherapy) to be curative. In this context, our findings suggest that the oncogene addiction model is not universally correct in its central thesis that cancer cell death is inevitable after loss of oncogenic protein function.
Introduction
A future strategy for cancer treatment is to target specific mutant proteins with drugs (genotype-specific therapy) that interfere with protein interactions by mutant proteins inside cells. A prerequisite of molecular target drug development is confirmation that a critical mutant molecule is a drug target by demonstrating susceptibility in preclinical mouse models. Further, the oncogene addiction model (Weinstein, 2002; Weinstein and Joe, 2008) posits that tumours rely on the continued expression of mutant oncogenes for maintenance of neoplasia such that tumour regression might be expected to result from ablating mutant protein function. However, few studies have been able to assess specific mutations in the context of the complex genetics and cell biology of tumour cells because there are few effective reagents. Further, there have been limited therapeutic assessments of specific functions of mutant oncogenic proteins for the same reason, other than limited examples (for example, targeting for HER-2, EGFR and BCR-ABL). Gene targeting (Shirasawa et al., 1993) or siRNA-mediated knock-down (Brummelkamp et al., 2002) have been used in some cases to assess efficacy of, for instance, the RAS target, but these cannot address specific functionality, such as protein-protein interactions.
RAS proteins are involved in cellular signal transduction by a diverse set of protein-protein interactions, including effector molecules, such as RAF, phosphoinositide 3-kinase (PI3K) and Ral guanosine diphosphate dissociation stimulator (Downward, 2003; Herrmann, 2003) . RAS gene mutations (KRAS, NRAS and HRAS) are common in a wide variety of human cancers (Forbes et al., 2006) resulting in constitutive activation of RAS and RAS-effector interactions and consequent aberrant signalling to the nucleus (Karnoub and Weinberg, 2008) . In addition, highly frequent mutations in epidermal growth factor receptor (EGFR) tyrosine kinase, PI3K p110a catalytic subunit (PI3KCA) and B-RAF are found in various human cancers (Weir et al., 2004) . In mouse models, numerous studies have demonstrated that Ras mutants and Ras effector mutants contribute to tumour formation and maintenance (Johnson et al., 2001; Dankort et al., 2007) and inducible transgenic models show that tumours in lung and melanoma harbouring mutant RAS can regress when mutant RAS expression is suppressed (Chin et al., 1999; Fisher et al., 2001) . Moreover, disruption of RAS-PI3K interaction by mutation on RAS binding domain of PI3K p110a can inhibit mutant Ras-mediated lung tumourigenesisis in mice (Gupta et al., 2007) . These data are encouraging the belief that inhibitors of RAS signalling pathways will be valuable in cancer therapy.
As a unique approach to evaluate that mutant RASeffector interaction on RAS signalling would be an effective target for cancer therapy, we have recently isolated a single immunoglobulin heavy chain variable domain fragment that specifically binds to the activated form of RAS (GTP-bound RAS) (Tanaka et al., 2007) and interferes with oncogenic RAS function inside the cell by competitively preventing RAS-effector interactions. This novel reagent, therefore, acts as drug surrogate, targeting the activated mutant RAS-specific protein interactions. The single domain (designated intracellular Domain antibody iDab#6-memb) binds with high affinity and specificity to the RAS switch I region, which is where the RAS effectors bind (Vetter and Wittinghofer, 2001 ). In the current study, we employed this specific iDab inhibitor of RAS-effector interactions to examine the potential role of mutant RAS-dependent signalling pathways in the initiation events of cancer and in the sustained growth of tumours that have mutations of RAS together with other oncogenes. We show that inhibiting mutant RASeffector interactions is sufficient to prevent tumour initiation and control cancer cell growth, but it is not remedial in the models used.
The anti-RAS iDab#6-memb binds specifically to the switch I region of the GTP-bound RAS (Tanaka et al., 2007) at locations where RAS effectors, such as PI3K and RAF, bind (Nassar et al., 1995; Pacold . The effect of anti-RAS iDab#6-memb on prevention of RAS downstream effector kinase phosphorylation was studied in serum-starved NIH3T3 cells ( Figure 1a ). These cells were transfected with plasmids expressing mutant HRASG12V, with or without iDab#6-memb and phosphorylation of extracellular regulated kinase 1/2 (ERK1/2) and AKT (phoshorylated through RAS-RAF or RAS-PI3K interactions, respectively) was detected by immunoblotting. Cells expressing HRASG12V without iDab#6-memb displayed phospho-ERK1/2 (Thr202/Tyr204) and phospho-AKT (Ser473), whereas those co-expressing HRASG12V and iDab#6-memb did not. This shows that iDab#6-memb inhibits mutant RAS-dependent ERK and AKT phospholyration. This interference with RAS-dependent ERK and AKT phosphorylation has an affect on the growth of colorectal adenocarcinoma (HCT116, SW480 and DLD1) or fibrosarcoma (HT1080) cell lines in culture, but is not wholly inhibitory or cytotoxic (Figure 1b) , consistent with reports with derivatives of these cell lines without mutant RAS (for example, Hkh-2 derived from HCT116, DKO-4 from DLD-1 and MCH603c8 from HT1080) (Plattner et al., 1996; Okada et al., 1998) . We have shown that the effect is specifically due to RAS-iDab binding as an expressed CDR-mutant form of iDab#6-memb with no RAS binding ability does not effect cell growth (Tanaka et al., 2007) , indicating that the effect is not simply a bystander effect. Our data are consistent with an oncogenic knock-down of RAS signalling as RAS-less cells do not grow in culture (Drosten et al., 2010) . The interference of RAS-effector interaction in normal mouse-lung organogenesis was determined in transgenic mice in which the iDab#6-memb is expressed in the Clara progenitor cell layer (the cells of origin of some lung tumours, especially adenocarcinomas, in experimental animal models and in humans (Kim et al., 2005) ) using a Clara cell 10 KDa protein (CC10) promoter to control expression. The specificity of lung epithelial expression of the CC10 transgene was confirmed using a CC10-Cre transgenic line expressing Cre recombinase from the CC10 promoter by mating with the lacZ reporter mouse ROSA26 (Soriano, 1999) , by histological analysis of b-galactosidase expression in epithelial cells lining lung bronchi and bronchioli of adult mouse lung (Figure 2a) . Expression of the iDab#6-memb protein in Clara cells was confirmed by western analysis in whole-lung tissue of CC10-iDab#6-memb transgenic mice (Figure 2b ). Also, we found no evidence of abnormal macroscopic lung development or dysfunction or microscopic changes to the epithelial layers in bronchi of CC10-iDab#6-memb transgenic mice compared with wild-type littermates (Figure 2c) . Further, the average lifetime of CC10-iDab#6-memb mice were similar to wild-type counterparts leading to the conclusion that targeting RAS-effector interaction in Clara cells throughout embryogenesis and adulthood is not deleterious per se. Figure 2 Cre recombinase and anti-RAS single domain expression in mouse lung Clara cells. Transgenic mouse line production is described in detail in the supplementary information. (a) Lungs were dissected from ROSA26 reporter mice crossed to CC10-Cre transgenic (TG) mice and whole-mount stained for b-galactosidase by perfusing X-gal staining solution (0.4 mg/ml X-gal, 5 mM MgCl 2 , 5 mM potassium ferrocyanide and 5 mM potassium ferricyanide in phosphate-buffered saline) through the trachea and immersing the whole lung in excess X-gal solution overnight at 37 1C. Top panels represent macroscopic images; middle and bottom panels are histological sections at Â 100 and Â 400, respectively. The right panels show b-galactosidase expression (blue-staining) in the bronchus and bronchioles compared with ROSA26 reporter only (left panels). (b) Lungs from CC10-iDab#6-memb transgenic mice (TG) and control mice (WT) were homogenized, protein immunoprecipitated with anti-FLAG antibody (the iDab#6-memb is FLAG tagged) immunoblotted with the anti-FLAG-tag antibody to detect 18-KDa iDab#6-memb (arrowed). The HT1080 cells were transiently transfected with pEF-iDab#6-memb expressing FLAG-tagged iDab#6-memb as positive control. (c) Representative lung histology of CC10-iDab#6-memb (TG) mice (left panels) and control mice (WT, right panels). Top and bottom panels are Â 100 and Â 400 magnification, respectively. In the bottom panels, the left-hand part shows bronchiolial regions Â 400 and the right-hand part show alveolar regions.
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To investigate the effect of targeting RAS-effector interaction in tumour initiation, we developed a spontaneous lung tumour model in which a conditional, Cre-dependent KRAS transgenic mouse line (conditional K-Ras V12 ) (Meuwissen et al., 2001 ) was crossed with CC10-Cre mice. Mutant RAS-dependent lung tumours developed in conditional K-Ras V12 mice expressing Cre, with most mice having multifocal and bilateral tumours by 150 days (Figures 3a and e) . A small number of spontaneous tumours, including those in lung (Figure 3b ), liver and breast appear at later stages in the conditional K-Ras V12 mice, presumably owing to a very low leakiness of mutant K-Ras V12 expression from the loxP-STOP cassette (data not shown). The array of tumour histologies found in the double transgenic mice ranged from atypical adenomatous hyperplasia (Figure 3g, left) , low-grade adenoma (Figure 3g , middle) to invasive adenocarcinomas (Figure 3g, right) .
The effect of co-expressing mutant RAS and the inhibitor of RAS-effector interactions (iDab#6-memb) on tumourigenesis was assayed in triple transgenic mice (K-Ras V12 ; CC10-Cre; and CC10-iDab#6-memb). In these mice, overt tumourigenesis was dramatically inhibited to below spontaneous lung tumour levels in K-Ras V12 mice in which few lung tumour foci appeared (Figures 3c and f) . However, these tumours may not have arisen from the Clara cell layer or iDab#6-memb may not be expressed sufficiently in the Clara cells and/ or tumour cells as immuno-staining with anti-CC10 antibody detected only bronchiolar epithelial cells and did not stain the adenoma and adenocarcinoma cells (compared with adjacent sections stained with haematoxylin and eosin, Supplementary Figures S1a, b) . These background tumours are completely suppressed in transgenic mice expressing K-RAS V12 and iDab#6-memb (Figure 3d ). These data testify that tumour initiation mediated by mutant KRAS in lung Clara cells is prevented by blocking RAS-effector interaction without any effects on normal lung cells.
As blockade of RAS-effector interaction prevents RAS-dependent tumour initiation, we evaluated effects of interfering with RAS-effector interaction in human cancer to mimic cancer therapeutics. For this purpose, we used conditional expression of the anti-RAS iDab#6-memb in a xenograft model with human cancer cells harbouring RAS mutation together with various additional gene mutations. Tetracycline-dependent expression of anti-RAS iDab#6-memb was established in two colon carcinomas (HCT116, with mutant KRAS plus b-catenin, PI3KCA and CDKN2A mutations (Ikediobi Figure S2) . Immunodeficient recipient mice were injected subcutaneously with either tetracycline-dependent iDab#6-memb HCT116 or tetracycline-dependent iDab#6-memb SW480 cells and their growth was monitored (Figures 4a, d and e) . When palpable tumours arose (more than 4 mm; day 4-7, Figure 4b top panel and 4f left panel) bioluminescence imaging was used to confirm cell viability (Supplementary Figure  S2a) . At that time, doxycycline was administered in drinking water and fed to one set of mice and not to a control group, followed by bi-weekly monitoring of tumour-cell viability by bioluminescence imaging and size determination (Figures 4a, b, e and f) . Although aggressive growth of the tumours occurred over an approximately 30-day period in mice without doxycycline, cessation of tumour development was observed from the initiation of doxycycline administration in both Figure S2a ) or parental TET-ON SW480 cells. 10 6 HCT116-tetON-iDab#6-memb-luc cells were injected subcutaneously into each flank of 6-8-week-old CB17/Icr-Prkdc scid /Crl SCID mice (Charles River) or 10 6 SW480-tetONiDab#6-memb-luc or parental SW480-tetON cells were injected into each flank of 6-8-week-old CD-1 nude mice. The mice were fed with normal diet and water until subcutaneous tumours reached palpable size (44 mm diameter). The mice were then divided into two groups and one of which was supplied with Doxycycline by drinking water (2 mg Dox/ml) and the Dox Diet (200 mg/kg) and another given no doxycycline (Dox (-)). Subcutaneous tumour growth was monitored by measuring tumour size twice a week with callipers and by bioluminescence imaging (BLI) as described in supplementary information. The assay was terminated when tumour sizes reached a maximum of 17 mm. After humane sacrifice, the mice were dissected and pathological and biological examinations were performed. (a) Growth of SW480-tetON-iDab#6-memb-luc tumours with and without Dox administration from day 5. At day 27, the dox administration was ceased in the dox ( þ ) group and tumour volumes monitored for a further 8 days (b) Tumour-cell viability was determined by BLI and images are shown from mice at day 4 and 17 (for the latter, two mice are shown having received doxycycline for 13 days (Dox þ )) (the colour overlay represents the photons per second; red being highest and blue being lowest emission). (c) Tumour tissues from mice implanted with SW480-tetON-iDab#6-memb-luc cells were examined after 27 days administration of doxycycline (dox þ ) or controls (Dox -) or 8 days after dox release ( þ /rel, at 35 days). The extracted proteins were immunoblotted with antibodies recognizing FLAG-tag on iDab#6-memb, anti-ERK1/2 or anti-phospho-ERK1/2 (Thr202/Tyr204) (p-ERK). (d) Growth curves of the parental TET-ON SW480 lacking iDab#6-memb (SW480-tetON). (e, f) Growth of HCT116-tetON-iDab#6-memb-luc tumours. Tumour-bearing mice were divided into two groups, Dox ( þ ) and Dox (from day 7. Tumour volumes were measured (e) and tumour viability was measured by BLI (panel f shows images at 4 and 27 days).
Blockading RAS signalling controls cancer growth T Tanaka and TH Rabbitts cases. At the time of termination of the control groups, the tumours in the doxycycline-treated mice had remained of minimal size. This is not simply an effect of antibody fragment expression per se (Tanaka et al., 2007) or of administering doxycycline per se, as SW480 cells lacking iDab#6-memb expression grew equally well in the presence or absence of doxycycline (Figure 4d ). The inhibition of tumour growth was accompanied by an effect of phosphorylation of ERK, which was reduced in the tumour biopsies from the SW480 doxycycline-treated mice (Figure 4c ). The status of the constituent cells in the stabilized tumours was studied in a group of mice bearing SW480 tumours that were inhibited by iDab#6-memb. After 27 days growth with doxycycline treatment in this group, viable cells remain as revealed by bioluminescence imaging and when inducer was removed, we observed a rapid re-establishment of tumour growth (approximate trebling of volume in 8 days, Figure 4a ). This demonstrates unequivocally the presence of live cancer cells in the tumour mass whose growth is controlled by the doxycycline-induced iDab#6-memb. Thus these cells can transit from the controlled state to one of rapid proliferation as soon as the RAS-effector blockade is released.
Our results validate RAS-effector and proteinprotein interactions as important components for tumour chemo-prevention and future therapy and show that the control of tumour growth, by physically interfering with RAS-effector interaction, can prevent tumour initiation and tumour growth of cancer cells even in the presence of mutations of other genes, such as TP53 or APC. Thus, inhibiting protein interaction between mutant RAS and effectors is sufficient to control cancer. It is extremely important to note that this therapeutic mimic approach controls cancer cell growth in tumours during the period when the anti-RAS iDab#6-memb inducer is administered, but relapse occurs when the inducer is removed. It may be that the length of therapy is a key parameter, as might have expected from the oncogene addiction model (Weinstein, 2002; Sharma and Settleman, 2007) , as using RAS as the target is not adequate to cure cancers. In addition, our results suggest that the oncogene addiction model is not true in all settings and thus that this may not always be the 'Achilles heal' of cancer addiction. Overall, the concept of cancer requiring multiple targeting fits better with data from many sources.
The concept of cancer therapy controlling a chronic phase of the disease rather than the panacea of a cure is recently becoming evaluated and debated. Our data show that cancer can potentially be made into a controllable disease (de facto cures), concurring with recent evaluations of cancer therapeutics suggesting that efforts to find ways to control the disease may be more beneficial than seeking cure (Gatenby, 2009 ). The effectiveness of targeting RAS-effector signal transduction interactions in cancer therapy offers one component in the control without unwanted side effects and suggests cures might be possible using combinations with other targeted drugs. Our data on the effectiveness of precisely targeting RAS-effector interactions in cancer therapy is underlined by our findings that blockade of these interactions in normal lung has no obvious side effects in a mouse preclinical model. The control of pre-cancerous conditions (for example, K-RAS-mutated colorectal adenoma) by targeting RAS-effector signal transduction interactions is also an exciting possibility to prevent progression to advanced life-threatening cancer in which chronic administration of targeted drugs may be efficacious. The iDab that we describe in this study may provide a template for future small-molecule drug development for use in cancer treatment.
